| Autor: |
Bielfeld, A.P., Schwarze, J.E., Verpillat, P., Lispi, M., Fischer, R., Hayward, B., Chuderland, D., D’Hooghe, T., Krussel, J.S. |
| Zdroj: |
Best Practice & Research Clinical Obstetrics & Gynaecology; 20230101, Issue: Preprints |
| Abstrakt: |
This non-interventional study compared the effectiveness of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) (2:1 ratio) versus r-hFSH alone for ovarian stimulation during assisted reproduction technology treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register (D·I·R). Numerically higher clinical pregnancy (29.8% [95% CI 28.2, 31.6] vs. 27.8% [26.5, 29.2]) and live birth (20.3% [18.7, 21.8] vs. 18.0% [16.6, 19.4]) rates were observed with r-hFSH:r-hLH versus r-hFSH alone. The treatment effect was consistently higher for r-hFSH:r-hLH compared with r-hFSH alone in terms of clinical pregnancy (RR 1.16 [1.05, 1.26]) and live birth (relative risk [RR] 1.16 [1.02, 1.31]) in a post-hoc analysis of women with 5–14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of r-hFSH:r-hLH for OS in women aged 35–40 years with normal ovarian reserve. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect